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Abstract 
 
Background 
Chordomas are rare tumours affecting the skull base. There is currently no clear consensus on the  
post-surgical radiation treatments that should be used after maximal tumour resection. However 
high dose proton beam therapy is an accepted option for post-operative radiotherapy to maximise 
local control, and in the UK, NHS approval for funding abroad is granted for specific patient criteria.   
 
Objectives 
To review the indications and efficacy of proton beam therapy in the management of skull-base 
chordomas. The primary outcome measure for review was the efficacy of proton-beam therapy in 
the prevention of local occurrence.  
 
Methods 
A systematic review of English and non-English articles using MEDLINE (1946-present) and 
EMBASE (1974-present) databases was performed. Additional studies  were searched for if 
referenced in other studies and not available on these databases. Search terms included 
chordoma or chordomas. The PRISMA guidelines were followed for reporting our findings as a 
systematic review.  
 
Results 
76 articles met the inclusion and exclusion criteria for this review. Limitations included the lack of 
documentation of the extent of primary surgery, tumour size, and lack of standardised outcome 
measures. Proton beam therapy given post operatively in the management of skull base 
chordomas resulted in better survival rates with less damage to surrounding tissue.  
 
 
Conclusions 
Proton beam therapy is a recommended treatment modality for post-operative radiation therapy to 
skull base chordomas . In comparison to other treatment modalities long-term local control and 
survival is perhaps improved with proton-beam therapy. Further studies are required to directly 
compare proton-beam therapy to other treatment modalities in selected patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
  
Chordomas are uncommon, aggressive primary bone tumours of the axial skeleton. The overall 
incidence of all chordomas is 0.08-0.5 cases per 100 000 individuals per year, and their incidence 
at the skull base location is 1 case per 2 million individuals per year. [1,2] They account for 1-4% of 
all malignant primary bone tumours. [3]  
 
In human embryos, the notochord forms the axial skeleton which later forms the skull base and 
vertebrae. [4] Normally, by 1-3 years of age the notochord is replaced by fibrocartilage tissue i.e. 
the notochord disintegrates. [5] In very few cases there are remnants of the notochord retained 
within intervertebral discs.[6] These remnants are termed notochord cell rests (NCRs). A chordoma 
is a cancer that arises from these NCRs.[7] There are three histopathological variants of 
chordomas: conventional; chondroid; or dedifferentiated. [3,8] 
 
Chordomas can theoretically arise from anywhere along the notochord, however in adults, three 
main sites have been identified that chordomas arise from, the skull, spine and sacrum. 
Chordomas arise from these 3 areas with roughly equal distribution. [8] Patients normally present 
by 4th-6th decade of life in clinic.[2,9] Children and adolescents may also present with these 
tumours.[10]  
 
Most skull base chordomas arise from the midline clivus[11] and have an infiltrative growth 
pattern.[12] They present a surgical challenge due to their proximity to neurovascular and bony 
structures as well as having a high recurrence rate. [13,14].The reported 5 year survival rate for 
chordomas of the clivus varies widely in the literature from 20-23% [9] to 95%[15]. Skull base 
chordomas and chondrosarcomas often present with impingement of adjacent neural structures in 
the skull base and cervical spine, and on average are symptomatic for a year before being 
diagnosed.[16] The most common presenting symptom are visual disturbances such as diplopia. 
[17] Skull base chordomas can present with epistaxis or intracranial haemorrhage [18,19] and, 
rarely, with endocrine impairment [8,20]. One case reports a giant clival chordoma that presented 
with pathological laughter[21] although this is extremely rare.  
 
The critical relation of a clival chordoma with the surrounding neural tissue dictates the treatment 
strategy. The aim of treatment is to avoid damage to the the surrounding brain parenchyma and 
cranial nerves from damage and to relieve any compression caused by a direct result of the 
tumour. Surgery is the mainstay of treatment of clival chordomas. External beam radiation is 
necessary to eradicate any residual tumour. [8] If possible, wide en-bloc resection is important to 
prevent recurrence. [22-25] This is achievable in the spine and sacrum, however satisfactory 
excision of such tumours in the skull base is much more difficult given the location and adjacent 
structures[26-27] as well as the infiltrative nature of these tumours into bone. [3] Local recurrence 
with surgery alone has been found to be at least 58% and is associated with significant mortality 
rates.[28] Numerous surgical approaches have been used and developed with the advances in 
image guidance and endoscopy, including revision of transsphenoidal and transoral techniques 
[8,29,30] Subfrontal, transcervical, high anterior cervical retropharyngeal [8,31,32] as well as other 
midline transfacial (transmandibular and transmaxillary) approaches to these tumours. [1] Lateral 
approaches include frontotemporal, orbitozygomatic, anterior transpetrosal, pre auricular 
infratemporal, combined supra and infra-tentorial transtemporal, and extreme lateral transcondylar. 
[31] The surgical pathway chosen to treat skull base chordomas and chondrosarcomas is normally 
based on the three subdivisions of the clivus (upper middle and lower). The specific surgical route 
is also affected by other factors including site, size, extent of local invasion of the tumour (i.e. 
breaching the dura) and surgical preference [22]. Patients age and co-morbidities may also 
influence selection of treatment.  Surgery is arguably the most important aspect of treatment of 
chordomas, and partial or subtotal resection leads to an increased chance of recurrence.[8,22-
25,33] 
Chemotherapy has also been proven to be ineffective for these slow growing tumours. Different 
drugs have been tried in the past to treat these without any positive benefits. Chordomas of the 
skull base therefore present a challenge in their management due to a number of reasons, and 
post surgical adjuvant radiotherapy is therefore critical to achieve tumour control. [34] There is 
good evidence to show that partial or sub-total surgical resection of clival chordomas and 
  
chondrosarcomas is associated with increased risk of recurrence, [8,22-25] and radiotherapy is 
considered effective only after maximal surgery. [35]  
 
Different radiation modalities have been used for clival chordoma patients post-surgical resection. 
Radiotherapy reduces post-operative complications as well decreasing the chance of local 
recurrence and metastasis. In 1996 particle beam therapy was suggested to be the most effective 
treatment for cranial base chordomas because to could deliver the necessary dose of radiation to a 
highly conformed field. [36] Hadrons were introduced to improve the radiobiological effect of 
radiation and to minimise injury to surrounding neural tissue. They are high-dose protons or 
charged particles which include carbon ions, helium or neon.  
 
Generally, an ideal radiation dose for chordomas is greater than 70Gy. [3] A more recent study 
suggested fractionated radiation of roughly 75Gy with once daily fractions of 1.8Gy. [37] The ability 
to deliver the ideal radiation dose is limited by the tolerance  of surrounding structures and the size 
of the lesion itself. [38] There are currently two schools of thought on radiation dose delivery to 
clival chordomas. One viewpoint favours sufficient irradiation, if necessary, even at the cost of 
exceeding the dose threshold of surrounding unaffected tissue. The other viewpoint emphasises 
adhering to dose thresholds even if that means a part of the tumour will not receive adequate 
radiation. [37] Whilst both approaches have their advantages each has a clear cost of either 
tumour control or complications of radiotherapy.  
 
There is currently little guidance on the post operative radiation management of  chordomas. High 
dose proton beam therapy is an accepted and available intervention however access to this 
treatment modality is often limited. Referral to these services requires specialist approval in the 
UK. The National Specialised commissioning team for specialised services has provided guidance 
on the referral for patients to receive proton beam therapy abroad in the management of skull base 
chordomas and chondrosarcomas. This review highlights the guidance and requirements for 
proton beam therapy to be approved, and reviews efficacy in comparison to other treatment 
modalities. An unpublished audit in 2014 by the UK Proton Overseas Programme highlighted a 
wide variation in imaging and surgical resection, leading to a high rejection rate for funding proton 
beam therapy, and therefore it is important for neurosurgeons to be aware of current 
recommendations. 
 
Methods 
  
A qualitative literature review of English and non-English articles was performed. Methods of the 
analysis and inclusion criteria were specified in advance and documented in a protocol. Studies 
included in this systematic review were any articles in which the primary tumour originated from the 
clivus. Patients of all age groups with a clival tumour were also included. Case series studies of 
more than 5 patients, Case studies with detailed post-radiation follow up data, case control studies 
and randomised clinical trials were reviewed. No language, publication date or publication status 
restrictions were imposed. All studies investigating post-operative radiation techniques for these 
tumours were reviewed.  
 
Articles looking only at chemotherapy or surgical technique only were excluded. Articles reporting 
on spinal or sacral chordomas were excluded. Rare presentations or metastases due to clival 
chordoma, other types of tumour (plasmocytoma and ecchordosis physaliphora) at or near the 
clivus were also excluded. Articles on whole genome analysis of skull base chordomas, histology 
and immunohistochemistry studies, surgical steps in cadaveric studies were also excluded.  
Our primary outcome measure was rate of local recurrence. Studies were identified by searching 
electronic databases MEDLINE (1946-present) and EMBASE (1974-present) databases was 
performed. Additional studies were searched for if referenced in other studies and not available on 
these databases. The last search was performed on 12th April 2015. 
 
We used the following search terms: chordoma OR chordomas AND clivus OR clival; chordoma(s) 
AND clivus AND radiation OR radiotherapy. Eligibility assessment was performed independently in 
an unblinded standardised manner by 2 reviewers. Disagreements between reviewers were 
  
resolved by consensus. There were no disagreements in the cases that were included or excluded. 
A data extraction sheet was developed. This was tested on ten randomly selected studies and 
refined accordingly. One review author extracted the data and the second author checked and 
analysed the data. Any disagreements were discussed between the two authors and if no 
consensus could be reached, the third author would decide. The information extracted from each 
paper was the number of cases, the radiotherapy treatment received and dose, the follow up, 
survival, time to recurrence, relative risk of mortality with different radiation modalities. To explore 
variability in study results we specified the following hypothesis before the analysis. We 
hypothesised that effect size may differ according to the methodological quality of the studies. The 
primary outcome measure was the relative risk of mortality reduction using different radiotherapy 
modalities.  
 
Results 
 
The search of MEDLINE and EMBASE identified 6408 articles relating to chordoma or chordomas, 
4077 articles relating to clivus or clival and 770 653 articles relating to radiotherapy. 258 articles 
were identified when these three search items were combined. These 258 articles were read, 
inclusion and exclusion criteria were applied and duplicates removed. This resulted in 12 articles 
investigating radiation therapy in the management of skull base chordomas.  
 
Six studies reported both survival and local control with the use of proton therapy. Table 1 
summarises these studies.  
 
Table 1: Survival and local control percentages of patients with skull base chordomas treated with 
different forms of post operative radiation therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There is a conflict in the predominance of base of skull chordomas by gender. One group reported 
a female predominance [2] whereas another more recent study reported a slight male 
predominance. [37] Four case series’ of a total of 99 patients treated with stereotactic radiosurgery 
(gamma knife) were studied. In 1970 Pearlman et al. were the first who described a link between 
  
the dose and response to treatment of photon radiation therapy in chordomas. [45] The data 
suggests a 5-year local control of 55.7% based on the average of three studies. The overall 5 year 
survival was 74%. [36-48] 
 
There are several limitations to this review. Different extents of surgery were not always 
documented (complete or incomplete excision, for example), different sizes of presenting tumours 
were often grouped together, and primary or revision surgeries were not necessarily specified. 
This heterogeneity of study variables, patient and disease characteristics, and often multiple 
different radiotherapy modalities in the surgical series, make direct comparisons unwise. 
 
Different radiation modalities have been used for chordomas, including stereotactic radiosurgery, 
proton beam and other heavy charged particles. Stereotactic radiosurgery damages the DNA of 
Study Number of 
patients 
Radiation % Local 
control 
% survival  Length of 
Follow up 
Radiation dosage 
Hug EB et.al. 1999  
Proton radiation therapy for 
chordomas and 
chondrosarcomas of the skull 
base [37] 
33 Synchroton;  
Passive scattering; 
energy 155-200MeV 
3 year 67% 
 
5-year 59% 
3-year 87% 
 
5 year 79% 
13-92months 
(mean 40) 
50.4-78.6Gy (1.8-
2Gy/fraction) 
Munzenrider JE et.al. 1999  
Proton therapy for tumours of 
the skull base [38] 
169 Cyclotron;  
Passive scattering;  
Energy 160MeV 
5 year 73% 
 
10 year 54% 
5 year 80% 
 
10 year 54% 
1-254 months 
(median 41 
months) 
66-83 Gy 
Hug EB et.al. 2002 
Proton radiotherapy in the 
management of paediatric 
base of skull tumours [39] 
10  
 
Cyclotron; 
Passive scattering; 
energy 160MeV 
Synchotron; 
passive scattering; 
energy 155-200MeV 
60% 60%   
Igaki H et.al. 2004 
Clinical results of proton 
beam therapy for skull base 
chordoma [40] 
13 Synchroton;  
Passive scattering; 
energy 250MeV 
3 year 67.1% 
 
5-year 46% 
3-year 84.6% 
 
5 year 66.7% 
  
Weber DC et.al 2005 
Results of spot-scanning 
proton radiation therapy for 
chordoma and 
chondrosarcoma of the skull 
base: The Paul Scherrer 
Institut experience [41] 
18 Cyclotron; 
spot scanning;  
energy 510MeV 
3 year 87.5% 3 year 93.8% 6-68 months 
(mean 29 months) 
68 CGE mean 
Noel G et.al. 2005 
Chordomas of the base of the 
skull and upper cervical spine. 
One hundred patients 
irradiated by a 3D conformal 
technique combining photon 
and proton beams [42] 
100 Cyclosynchroton; 
Passive scattering;  
energy 201MeV 
2 year 86.3% 
 
4 year 53.8% 
2 year 94.3% 
 
5 year 80.5% 
median 31 months 67Gy 
Benk V et.al. 1995 Base of 
Skull and cervical spine 
chordomas in children treated 
by high dose irradiation 
18 160MeV Cyclotron 5 yr 78% 5 yr 68% mean 72 months 69 CGE, 1.8CGE/fraction 
Debus J et al. 1997 Brainstem 
tolerance to conformal 
radiotherapy of skull base 
tumours 
367 160MeV Cyclotron 10 yr 84% 5 yr 94%  10yr 
86% 
6months - 21.4 
years (mean 
42.5months) 
67.8 CGE 
Habrand JL et al.1988 
Protontherapy in pediatric 
skull base and cervical canal 
chodromas. long term 
outcome of the orsay series 
34 160MeV Cyclotron   30-68months 
(mean 52) 
66.6-74.4CGE 
Wei HJ. et al. Endoscopic 
resection of chordomas in 
different clival regions 2009 
9 IMRT 100% 100% 6months - 3 years not stated 
Ito E. et.al. 2009 Long-term 
control of clival chordoma with 
initial aggressive surgical 
resection and gamma knife 
radiosurgery for recurrence 
13 (4 initial, 10  
on recurrence) 
Gamma Knife 75% on initial 
treatment 
2 year - 77.9%            
5 year- 47.9% 
(progression free 
Survival) 
mean 71.2months  
Ahmed R. et.al. Disease 
outcomes for skull base and 
spinal chordomas: a single 
centre experience. 2015  
30 HS-FSRT 70%  6.3 years  
 
  
tumour cells, and aims to prevent tumour cell division. Sources of radiation include Cobalt-60 
source for Gamma-knife, whereas linear accelerators are used to provide radiation in Cyber-knife 
therapy. 
 
Proton therapy is, generally, used in cases where conventional radiotherapy is insufficient to 
control local tumour progression and whenever critical normal tissue is in close proximity to the 
tumour. [49] In proton therapy multiple beams are designed based on the target volume to deliver 
effective radiation dose without damage to surrounding tissue in the skull base, 3 dimensional 
treatment planning and proton radiation therapy is therefore the most effective method to deliver 
high dose radiation to a lesion following surgical resection. [50] 
 
Among the advantages of protons is the sudden dose decline beyond the target. [3] This is 
because of the characteristic Bragg Peak of proton beam radiation. [36] Another benefit is that high 
dose protons or charged particles allow higher doses of radiation to be delivered to the target 
volume. This reduces the radiation injury and improves radiobiological effect. [51]  
 
There is significant heterogeneity in the literature on chordomas and their management. This is 
especially true in the role adjuvant radiotherapy plays in relation to extent of surgical resection. 
[52,53] In addition to proton beam therapy, gamma knife, charged heavy particle therapy and 
intensity modulated radiation therapy (IMRT) have also been used. There remains no evidence of 
clinical superiority of one radiotherapy modality over another.  
 
 
 
Currently patients in England requiring high energy proton beam therapy must be referred to a 
Proton Clinical reference panel (PCRP) for approval for consideration of having proton beam 
therapy abroad. [54] The Department of Health are also taking forward a strategy to commission 
high energy proton therapy in England, and this service is expected to be available within the next 
few years. Treatment centres abroad have placed constraints on whom they will accept through 
the NHS funded route based on local criteria of suitability. Patients are referred to the PCRP by the 
clinical oncologist who reviewed the patient locally.  
 
There is good evidence that maximal safe surgical resection is necessary to provide the best 
possible prognosis, and indeed, treatment centres will not accept cases of skull base chordomas if 
pre and post op MRI imaging is not available, or it is considered that insufficient surgery has been 
performed.  A number of general restrictions also exist for referral to proton beam therapy. [figure 
1] 
 
Figure 1: Recommendations for Proton Beam Therapy 
 
Key principles  to consider when applying for Proton beam therapy funding in the UK. 
Treatment should be given with curative intent 
Patients will have good performance status (WHO 0-1 performance status) [50] 
No other diagnoses that will limit 5-year survival or make prolonged period abroad difficult to manage 
There should be no metastatic disease 
Re-treatment cases will not be accepted 
Patient weight at time of referral should not exceed 150kg 
Maximal safe surgery has been performed 
  
Key principles  to consider when applying for Proton beam therapy funding in the UK. 
Adequate clearance from eloquent nervous structures, eg. 3mm clearance from the brainstem, and 5mm 
clearance from the optic chiasm. 
Avoid metal implants at the craniocervical junction unless unstable, and if necessary, avoid screws or 
cross-bars at the level of the tumour resection. 
 
 
 
At present proton therapy seems to be more promising in achieving better long term local control 
and overall survival. This is shown by better overall percentages. 
 
Implications for surgery 
 
Post-operative imaging is mandatory, to decide residual volume of tumour, and clearance from 
eloquent structures. If insufficient clearance has been achieved, then further surgery should be 
considered prior to referral for proton beam therapy. Complete resection is the goal, within the 
constraints of safety and minimising complications. However, surgery inevitably carries some risk, 
and this needs to be weighed by the surgeon, oncologist and patient, on a case-by-case basis. 
Since chordomas are rare tumours and the surgery itself is challenging, operations should be 
performed in specialised neurosurgical centres with sufficient volume to maintain surgical 
expertise, access to radiological and other supporting services, within the context of 
multidisciplinary team discussion. Specialist centres should have access to the full range of 
technical approaches required (endoscopic, anterior, lateral and posterior skull base approaches),  
All centres should audit their quality of surgery, complication rates, radiological outcomes, and 
patient survival, which allows service monitoring and improvement. This may entail fewer surgical 
centres in the UK performing greater numbers of operations in the future, with the goal of 
improving patient benefit. 
 
 
Conclusions 
 
In the UK, proton therapy is felt to be the most effective radiation modality in the management of 
post-resection skull base chordomas. Local control and survival are likely to be improved when 
compared to other radiation modalities. Further studies must be conducted to gain a better 
understanding of the indications, shortcomings and areas of improvement for this technique, and 
currently there is no level 1 evidence comparing different post-operative radiotherapy techniques.  
Although proton beam therapy for chordomas is to be recommended, other modalities such as 
stereotactic radiosurgery, intensity modulated radiotherapy, or other heavy particles, continue to 
have a role in treatment.  
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